Press Release
Article Category
![](https://parsianpharma.com/wp-content/uploads/2024/01/breast-canser-awareness.jpg)
Breast Cancer Awareness Month
Breast Cancer Awareness October is Breast Cancer Awareness Month, an annually campaign to raise
![Soft Tissue Sarcoma](https://parsianpharma.com/wp-content/uploads/2024/01/Soft-Tissue-Sarcoma.jpg)
Soft Tissue Sarcoma
Tyrosine kinase inhibitors in Soft Tissue Sarcomas treatment Sarcomas are a group of
![GISTs](https://parsianpharma.com/wp-content/uploads/2024/01/Gastrointestinal-stromal-tumors.jpg)
Gastrointestinal stromal tumors (GISTs)
Tyrosine Kinase Inhibitors Used in Gastrointestinal stromal tumors (GISTs) Introduction A gastrointestinal stromal tumor
![Hepatocellular carcinoma](https://parsianpharma.com/wp-content/uploads/2024/01/Hepatocellular-carcinoma-HCC.jpg)
Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) Liver cancer is a global health challenge, with an estimated
![Mantle Cell Lymphoma](https://parsianpharma.com/wp-content/uploads/2024/01/Ibrutinib-2.jpg)
Mantle Cell Lymphoma
Recent Results Show ibrutinib-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or
![](https://parsianpharma.com/wp-content/uploads/2024/01/thyroid-cancer.jpg)
Overview of Thyroid Cancer
Targeted therapies used in the Treatment of Thyroid Cancer Introduction Thyroid cancer is a
![EGFR-TKI](https://parsianpharma.com/wp-content/uploads/2024/01/EGFR-TKI.jpg)
EGFR-TKI
The Clinical Efficacy of Combinatorial Therapy of EGFR-TKI and Crizotinib in Overcoming MET amplification-mediated Resistance
![Crizotinib](https://parsianpharma.com/wp-content/uploads/2024/01/Crizotinib-0222.jpg)
Benefits of Crizotinib in Advanced NSCLC
Benefits of Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Abstract: Non-small-cell lung
![Melonama](https://parsianpharma.com/wp-content/uploads/2024/01/Unti222tled-2.jpg)
Melonama Monday, May Is Melanoma
Melonama Monday, May Is Melanoma Awareness Month It is Good to Know about